Low anti-anxiety hormone levels may up postpartum depression | WeForNews | Latest News, Blogs Low anti-anxiety hormone levels may up postpartum depression – WeForNews | Latest News, Blogs
Connect with us

Health

Low anti-anxiety hormone levels may up postpartum depression

Published

on

Pregnant Women

New York, March 15 : Pregnant women having lower levels of an anti-anxiety hormone in their second trimester had an increased chance of developing postpartum depression, a study has shown.

Postpartum depression — depression that occurs after childbirth — affects early bonding between the mother and child.

According to the study, appearing in the journal Psychoneuroendocrinology, a woman with an allopregnanolone hormone level of about 3.75 nanograms per milli-liter had a 33 per cent likelihood of developing the disorder.

While a woman having 7.5 nanograms per milli-liter had a 1.5 per cent chance of developing postpartum depression.

For every additional nanogram per milli-liter increase in allopregnanolone, the risk of developing postpartum depression dropped by 63 per cent, the researchers said.

Further, the risk was particularly high in women already diagnosed with mood disorders, such as major depression or bipolar disorder.

anti-anxiety

“Many earlier studies haven’t shown postpartum depression to be tied to actual levels of pregnancy hormones, but rather to an individual’s vulnerability to fluctuations in these hormones and they didn’t identify any concrete way to tell whether a woman would develop postpartum depression,” said Lauren M. Osborne, Assistant Professor at the Johns Hopkins University in Maryland, US.

“Every woman has high levels of certain hormones, including allopregnanolone, at the end of pregnancy, so we decided to look earlier in the pregnancy to see if we could tease apart small differences in hormone levels that might more accurately predict postpartum depression later,” Osborne added.

For the study, the team included 60 pregnant women between the ages of 18 and 45, all who had been previously diagnosed with a mood disorder.

Using the blood samples, the researchers measured the blood levels of progesterone and allopregnanolone, a by-product made from the breakdown of progesterone and known for its calming, anti-anxiety effects.

No relationship was found between progesterone levels in the second or third trimesters and the likelihood of developing postpartum depression.

However, a link between postpartum depression and diminished levels of allopregnanolone levels in the second trimester was observed.

Health

Russia: Putin orders mass COVID-19 vaccinations; health minister claims one lakh already received Sputnik V

Museums, theatres and concert halls would be closed to the public in the city of more than 5 million people for the duration of Russia’s New Year holidays, from December 30 to January 10.

Published

on

Russian President Vladimir Putin

Russian Health Minister Mikhail Murashko on Wednesday said more than 100,000 people had already been vaccinated against COVID-19, as Moscow presented its Sputnik V vaccine to the United Nations over video link.

President Vladimir Putin earlier ordered authorities to begin mass voluntary vaccinations next week. Russia will have produced two million vaccine doses within the next few days, Putin said.

Russia said last month that its Sputnik V jab was 92% effective at protecting people from COVID-19 according to interim results.

“Let’s agree on this – you will not report to me next week, but you will start mass vaccination…let’s get to work already,” Putin told Deputy Prime Minister Tatiana Golikova.

Golikova said large-scale vaccination could begin on a voluntary basis in December.

The rise in infections has slowed since reaching a high on November 27, with 25,345 new cases reported on Wednesday.

Russia has resisted imposing lockdowns during the second wave of the virus, preferring targeted regional curbs.

With 2,347,401 infections, Russia has the fourth-largest number of COVID-19 cases in the world behind the United States, India and Brazil. It has recorded 41,053 deaths related to COVID-19 since the start of the pandemic.

The Kremlin earlier gave assurances that Russians were first in line to be vaccinated, with Moscow also discussing supply deals with other countries.

“The absolute priority are Russians,” Kremlin spokesman Dmitry Peskov said. “Production within Russia, which is already being developed, will meet the needs of Russians.”

Authorities in St Petersburg, which reported 3,684 new infections on Wednesday, ordered bars and restaurants to close from December 30 until January 3, to combat the rise in cases there, the RIA news agency reported.

Museums, theatres and concert halls would be closed to the public in the city of more than 5 million people for the duration of Russia’s New Year holidays, from December 30 to January 10.

Continue Reading

Health

UK Approves Pfizer-BioNTech Covid Vaccine For Use, First In The World

The country has ordered up to 40 million doses of the vaccine that is said to offer 95 per cent protection.

Published

on

COVID-19 Vaccine

Pfizer and BioNTech say they’ve won permission Wednesday for emergency use of their Covid-19 vaccine in Britain, the world’s first coronavirus shot that’s backed by rigorous science — and a major step toward eventually ending the pandemic.

The move makes Britain one of the first countries to begin vaccinating its population as it tries to curb Europe’s deadliest Covid-19 outbreak.

Other countries aren’t far behind: The U.S. and the European Union also are vetting the Pfizer shot along with a similar vaccine made by competitor Moderna Inc.

Pfizer said it would immediately begin shipping limited supplies to the U.K. — and has been gearing up for even wider distribution if given a similar nod by the U.S. Food and Drug Administration, a decision expected as early as next week.

But doses everywhere are scarce, and initial supplies will be rationed until more is manufactured in the first several months of next year.

Pfizer CEO Albert Bourla called the U.K. decision “a historic moment.”

“We are focusing on moving with the same level of urgency to safely supply a high-quality vaccine around the world,” Bourla said in a statement.

While the U.K. has ordered enough Pfizer vaccine for 20 million people, it’s not clear how many will arrive by year’s end and adding to the distribution challenges is that it must be stored at ultra-cold temperatures.

Two doses three weeks apart are required for protection. First in line, the U.K. government says, are frontline health care workers and nursing home residents, followed by older adults.

British regulators also are considering another shot made by AstraZeneca and Oxford University. But Prime Minister Boris Johnson has warned “we must first navigate a hard winter” of restrictions to try to curb the virus until there’s enough vaccine to go around.

Every country has different rules for determining when an experimental vaccine is safe and effective enough to use. Intense political pressure to be the first to roll out a rigorously scientifically tested shot coloured the race in the U.S. and Britain, even as researchers pledged to cut no corners. In contrast, China and Russia have offered different vaccinations to their citizens ahead of late-stage testing.

The shots made by U.S.-based Pfizer and its German partner BioNTech were tested in tens of thousands of people. And while that study isn’t complete, early results suggest the vaccine is 95% effective at preventing mild to severe Covid-19 disease. The companies told regulators that of the first 170 infections detected in study volunteers, only eight were among people who’d received the actual vaccine and the rest had gotten a dummy shot.

“This is an extraordinarily strong protection,” Dr. Ugur Sahin, BioNTech’s CEO, recently told The Associated Press.

The companies also reported no serious side effects, although vaccine recipients may experience temporary pain and flu-like reactions immediately after injections.

But experts caution that a vaccine cleared for emergency use is still experimental and the final testing must be completed. Still to be determined is whether the Pfizer-BioNTech shots protect against people spreading the coronavirus without showing symptoms. Another question is how long protection lasts.

The vaccine also has been tested in only a small number of children, none younger than 12, and there’s no information on its effects in pregnant women.

Continue Reading

Cities

Delhi hospitals witnessing probable cases of Covid reinfection

However, Dr. Chatterjee asserted that more follow up is needed to confirm the reported cases’ categorization into reinfection as it may trigger panic among the public.

Published

on

By

SNG001 Coronavirus Med

New Delhi, Dec 2 : As the national capital continues to battle the third and the deadliest surge of the Covid-19 pandemic, another threat related to the coronavirus has started to loom large over its horizon — the danger of reinfection of the viral disease.

The hospitals across the city have begun to report probable cases of reinfection of the disease. The instances may be relatively less or insignificant in numbers, but are enough to ring alarms.

Two days ago Sir Ganga Ram Hospital reported two cases that were claimed as reinfection of the Covid-19. The cases included a man with comorbidity and a healthcare staff of the hospital itself. The hospital claimed that the man was found to be reinfected in mere 25 days of testing negative, while the staff was found reinfected within two months of her recovery from the previous episode.

The Indraprastha Apollo Hospital has also seen similar cases lately. The hospital told IANS that at least five cases had been reported, which indicated probable reinfection of the Covid-19 disease.

Dr. Suranjit Chatterjee, Senior Consultant, Internal Medicine at Apollo informed that one of his patients was readmitted to the facility as he tested positive again after two and half months of recovery from the first episode.

“The patient was comorbid. He was treated for 10 days during the first instance of the infection and was discharged. However, two and half months later, he complained of the onset of Covid induced symptoms and when tested, found positive,” he said.

Meanwhile, Aakash healthcare informed IANS that it had received two definite reinfection cases recently, where one of the patients tested positive two months after recovering from the previous episode.

“Ten days ago, the patent was admitted with high grade fever, cough and difficulty in breathing. He had obesity as an underlying condition. He received eight days of treatment before the discharge,” informed Dr. Akshay Budhraja, Consultant, Department of Pulmonary and Sleep Medicine at Aakash.

“During our investigation, the patients revealed that he had tested positive in early September when his whole family had contracted the virus. Since the severity of the disease was mild in nature, he opted for home isolation and tested negative after 21 days. However, he started having breathing issues and fever in late October and when he underwent the RT-PCR test, the result came positive,” he added.

While Dr. Budhraja said that the antibody test on the patient was not followed, he claimed that the findings of investigations such as CT scan and blood test implied that he did not have the relapse but a confirmed re-infection.

Dr. Sandeep Nayar, Sr. Director and Head, Centre for Chest and Respiratory Disease, BLK Super Speciality Hospital also told IANS that his hospital has been receiving patients who have probable indicators of having reinfection of the disease. “I have just seen a patient today who again tested positive for Covid-19 after recovery with a complaint of mild symptoms,” he added.

However, Dr. Chatterjee asserted that more follow up is needed to confirm the reported cases’ categorization into reinfection as it may trigger panic among the public.

“Despite all the indicators suggesting the cases as reinfection of the viral disease, we need to be more careful before labelling them as the same as it could create panic among the public. To ascertain whether the cases are reinfection, reactivation or relapse of the disease would require a thorough study and a proper follow up,” he cautioned.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.